# OnCo record paper-anbl1221-irinotecan-temozolomide-dinutuximab-mody-lancet-oncol-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-anbl1221-irinotecan-temozolomide-dinutuximab-mody-lancet-oncol-2017/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-anbl1221-irinotecan-temozolomide-dinutuximab-mody-lancet-oncol-2017" ;
  schema:name "ANBL1221: irinotecan-temozolomide with temsirolimus or dinutuximab in relapsed or refractory neuroblastoma"@en ;
  schema:description "In children whose neuroblastoma had come back, adding the anti-GD2 antibody dinutuximab to irinotecan and temozolomide shrank the cancer in half of them, while adding temsirolimus almost never did."@en ;
  schema:url <https://onco.cc/key-papers/paper-anbl1221-irinotecan-temozolomide-dinutuximab-mody-lancet-oncol-2017/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(17)30355-8>, <https://pubmed.ncbi.nlm.nih.gov/28549783/> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(17)30355-8> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "Mody R, Naranjo A, Van Ryn C, et al." ;
  onco:cancers <https://onco.cc/cancers/neuroblastoma-high-risk/>, <https://onco.cc/cancers/neuroblastoma/> ;
  onco:drugs <https://onco.cc/drugs/dinutuximab/>, <https://onco.cc/drugs/irinotecan/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/drugs/temsirolimus/> ;
  onco:trials <https://onco.cc/trials/anbl1221/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .